Login

Financial Snapshot

Revenue
TTM
$1.597M
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$26.54M
Current Assets
2025 Q4
Current Liabilities
2025 Q4
Current Ratio
2025 Q4
345.66%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
$3.922M
Book Value
2025 Q4
5.592M
Cash
2025 Q4
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$16.59M

Stock Price

Loading...
Market Cap: $19.78 Million

About Can Fite Biopharma Ltd

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 5 full-time employees. The company went IPO on 2005-09-22. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Industry: Pharmaceutical Preparations Peers: Enlivex Ltd Collplant Biotechnologies Ltd Protalix Biotherapeutics Inc Gamida Cell Ltd. Kamada Ltd Urogen Pharma Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support